Collection
CAR T-cell therapy in cancer
- Submission status
- Closed
Cancer therapy using chimeric antigen receptor (CAR)-T-cells is one of the most exciting recent developments in cancer therapy. To date CAR-T-cells have been successfully used to treat persons with hematologic cancers, especially acute lymphoblastic leukemia (ALL), lymphomas and plasma cell myeloma (PCM). Although most studies are in persons with advanced lymphomas, some controversial data suggest CAR-T-cell therapy might replace autologous hematopoietic cell transplants in persons failing conventional therapies. The CAR-T-cell constructs are directed against lineage-related targets such as CD19 and CD20. Although studies of using CAR-T-cells to treat other hematologic cancers such as acute myeloid leukemia (AML) and solid cancers are progressing, these targets have proved more elusive and no CAR-T-cell therapy is yet approved. In this collection we include key research published in the journals Leukemia, Blood Cancer Journal, Cancer Gene Therapy, Journal of Cancer Research and Clinical Oncology and Medical Oncology. The editors welcome future submissions to expand this collection further.
Articles (101 in this collection)
-
-
Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)
Authors (first, second and last of 10)
- Xinran Wang
- Jiankun He
- Yueping Liu
- Content type: Research
- Open Access
- Published: 28 January 2024
- Journal of Cancer Research and Clinical Oncology
- Article: 43
-
Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7
Authors (first, second and last of 13)
- Michael C. Kann
- Emily M. Schneider
- Max Jan
- Content type: Article
- Published: 20 December 2023
- Leukemia
- Pages: 590 - 600
-
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
Authors (first, second and last of 7)
- Qingming Wang
- Runhong Wei
- Zhi Cheng
- Content type: Article
- Open Access
- Published: 15 December 2023
- Cancer Gene Therapy
- Pages: 420 - 426
-
The intrinsic defects of T cells impact the efficacy of CAR-T therapy in patients with diffuse large B-cell lymphoma
Authors (first, second and last of 11)
- Jinrong Zhao
- Chong Wei
- Daobin Zhou
- Content type: Article
- Open Access
- Published: 14 December 2023
- Blood Cancer Journal
- Article: 186
-
Enhancing CAR-T cells: unleashing lasting impact potential with phytohemagglutinin activation in in vivo leukemia model
Authors (first, second and last of 17)
- Berranur Sert
- Gamze Gulden
- Cihan Tastan
- Content type: Article
- Published: 14 December 2023
- Cancer Gene Therapy
- Pages: 387 - 396
-
Development of PD-1 blockade peptide-cell conjugates to enhance cellular therapies for T-cell acute lymphoblastic leukemia
Authors (first, second and last of 7)
- Quanxiao Wang
- Hongxing Huang
- Hua Wang
- Content type: Original Paper
- Published: 11 December 2023
- Medical Oncology
- Article: 14
-
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Authors (first, second and last of 15)
- Chenggong Li
- Jia Xu
- Heng Mei
- Content type: Article
- Open Access
- Published: 17 October 2023
- Leukemia
- Pages: 149 - 159
-
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
Authors (first, second and last of 19)
- Surbhi Sidana
- Hitomi Hosoya
- Murali Janakiram
- Content type: Correspondence
- Open Access
- Published: 13 October 2023
- Blood Cancer Journal
- Article: 158
-
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
Authors (first, second and last of 14)
- Jingyu Xiang
- Jessica M. Devenport
- John F. DiPersio
- Content type: Article
- Open Access
- Published: 05 October 2023
- Leukemia
- Pages: 2448 - 2456
-
Involving stemness factors to improve CAR T-cell-based cancer immunotherapy
Authors (first, second and last of 11)
- Sara Abdalrazzaq M. Noraldeen
- Irodakhon Rasulova
- Sepideh Karkon Shayan
- Content type: Review Article
- Published: 01 October 2023
- Medical Oncology
- Article: 313
-
CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies
Authors (first, second and last of 29)
- Shiqi Li
- Xinxin Wang
- Sanbin Wang
- Content type: Article
- Published: 12 September 2023
- Leukemia
- Pages: 2176 - 2186
-
Who wins the combat, CAR or TCR?
Authors
- Kun Yun
- Elizabeth L. Siegler
- Saad S. Kenderian
- Content type: Review Article
- Published: 25 August 2023
- Leukemia
- Pages: 1953 - 1962
-
Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer
Authors (first, second and last of 8)
- Yuankui Zhu
- Dianbao Zuo
- Mingqian Feng
- Content type: Research
- Published: 23 August 2023
- Journal of Cancer Research and Clinical Oncology
- Pages: 15027 - 15038
-
Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy
Authors
- Preeti Dabas
- Adithi Danda
- Content type: Review Article
- Published: 22 August 2023
- Medical Oncology
- Article: 275
-
Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
Authors (first, second and last of 16)
- William G. Breen
- Jason R. Young
- Yi Lin
- Content type: Article
- Open Access
- Published: 18 August 2023
- Blood Cancer Journal
- Article: 127
-
Chimeric antigen receptor T cells march into T cell malignancies
Authors
- Jie Tang
- Xudong Zhao
- Content type: Review
- Published: 19 July 2023
- Journal of Cancer Research and Clinical Oncology
- Pages: 13459 - 13475
-
Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)
Authors (first, second and last of 19)
- Simone Cesaro
- Malgorzata Mikulska
- Livio Pagano
- Content type: Correspondence
- Open Access
- Published: 17 July 2023
- Leukemia
- Pages: 1933 - 1938
-
Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome
Authors (first, second and last of 10)
- Lucia Salz
- Alexander Seitz
- Wolfgang Wagner
- Content type: Article
- Open Access
- Published: 14 July 2023
- Leukemia
- Pages: 1868 - 1878
-
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia
Authors (first, second and last of 11)
- Ibrahim Aldoss
- Samer K. Khaled
- Stephen J. Forman
- Content type: Correspondence
- Open Access
- Published: 12 July 2023
- Blood Cancer Journal
- Article: 107
-
A novel TREM1/DAP12-based multiple chain CAR-T cell targets PTK7 in ovarian cancer therapy
Authors (first, second and last of 6)
- Tongpeng Xu
- Chen Wang
- Ming Sun
- Content type: Original Paper
- Published: 05 July 2023
- Medical Oncology
- Article: 226
-
T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancer
Authors (first, second and last of 6)
- Xinshan Xie
- Xiaobin Li
- Sheng Xiong
- Content type: Research
- Published: 04 July 2023
- Journal of Cancer Research and Clinical Oncology
- Pages: 11561 - 11570
-
Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells
Authors (first, second and last of 8)
- Yeye Zhou
- Bin Zhang
- Shibiao Sang
- Content type: Research
- Published: 03 July 2023
- Journal of Cancer Research and Clinical Oncology
- Pages: 11549 - 11560
-
CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process
Authors (first, second and last of 19)
- Bianca Altvater
- Sareetha Kailayangiri
- Claudia Rossig
- Content type: Article
- Open Access
- Published: 30 June 2023
- Cancer Gene Therapy
- Pages: 1355 - 1368
-
T cells with split CARs specific for NKG2D ligands and PD-L1 exhibit improved selectivity towards monocyte-derived cells while effective in eliminating acute myeloid leukaemia in vivo
Authors (first, second and last of 7)
- Lu Sun
- Guangyi Jiang
- Jianqing Zhu
- Content type: Research
- Published: 03 June 2023
- Journal of Cancer Research and Clinical Oncology
- Pages: 10189 - 10201
-
CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months
Authors (first, second and last of 15)
- Zhenzhen Yao
- Bin Gu
- Ying Wang
- Content type: Correspondence
- Open Access
- Published: 10 May 2023
- Blood Cancer Journal
- Article: 75
-
Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL
Authors (first, second and last of 12)
- Yan Qiu
- Chao-Ling Wan
- Sheng-Li Xue
- Content type: Correspondence
- Open Access
- Published: 03 May 2023
- Blood Cancer Journal
- Article: 66
-
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
Authors (first, second and last of 21)
- D. Nixdorf
- M. Sponheimer
- M. Subklewe
- Content type: Article
- Open Access
- Published: 27 April 2023
- Leukemia
- Pages: 1298 - 1310
-
A review on emerging targeted therapies for the management of metastatic colorectal cancers
Authors
- Rohitas Deshmukh
- Mahendra Prajapati
- Ranjit K. Harwansh
- Content type: Review Article
- Published: 25 April 2023
- Medical Oncology
- Article: 159
-
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
Authors (first, second and last of 16)
- Yinqiang Zhang
- Chenggong Li
- Heng Mei
- Content type: Article
- Open Access
- Published: 25 April 2023
- Blood Cancer Journal
- Article: 61
-
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
Authors (first, second and last of 22)
- Sining Liu
- Xinyue Zhang
- Xiaowen Tang
- Content type: Article
- Open Access
- Published: 24 April 2023
- Blood Cancer Journal
- Article: 60
-
CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies
Authors (first, second and last of 7)
- Mohammed Hikmat Faeq
- Maysoon Al-Haideri
- Shadan Modaresahmadi
- Content type: Review Article
- Published: 21 April 2023
- Medical Oncology
- Article: 155
-
CD27 agonism coordinates with CD28 and 4-1BB signal to augment the efficacy of CAR-T cells in colorectal tumor
Authors (first, second and last of 10)
- Chengcheng Zhang
- Jiankun Jia
- Cheng Qian
- Content type: Original Paper
- Published: 22 March 2023
- Medical Oncology
- Article: 123
-
Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis
Authors (first, second and last of 5)
- Magdi Elsallab
- Moataz Ellithi
- Mohamed Abou-el-Enein
- Content type: Article
- Open Access
- Published: 07 February 2023
- Cancer Gene Therapy
- Pages: 845 - 854
-
RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function
Authors (first, second and last of 7)
- Xiuxiu Zhu
- Wuling Li
- Cheng Qian
- Content type: Original Paper
- Published: 03 February 2023
- Medical Oncology
- Article: 89
-
Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma
Authors (first, second and last of 20)
- Alexander M. Leipold
- Rudolf A. Werner
- Leo Rasche
- Content type: Article
- Open Access
- Published: 31 January 2023
- Leukemia
- Pages: 650 - 658
-
Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy
Authors (first, second and last of 17)
- Thomas Walter Georgi
- Lars Kurch
- Vladan Vučinić
- Content type: Research
- Open Access
- Published: 20 January 2023
- Journal of Cancer Research and Clinical Oncology
- Pages: 6131 - 6138
-
Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma
Authors (first, second and last of 15)
- Aldo A. Acosta-Medina
- Isla McKerrow Johnson
- Hassan B. Alkhateeb
- Content type: Correspondence
- Open Access
- Published: 05 January 2023
- Blood Cancer Journal
- Article: 7
-
Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Authors (first, second and last of 8)
- Konstantinos Drougkas
- Konstantinos Karampinos
- Elias Kotteas
- Content type: Review
- Open Access
- Published: 24 December 2022
- Journal of Cancer Research and Clinical Oncology
- Pages: 2709 - 2734
-
IL-2/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K/AKT and ERK1/2 pathways
Authors (first, second and last of 10)
- Liwei Liu
- Yan Cheng
- Bo Liu
- Content type: Research
- Published: 06 December 2022
- Journal of Cancer Research and Clinical Oncology
- Pages: 5547 - 5557
-
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
Authors (first, second and last of 33)
- Ana Alarcon Tomas
- Joshua A. Fein
- Roni Shouval
- Content type: Article
- Published: 05 November 2022
- Leukemia
- Pages: 154 - 163
-
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
Authors (first, second and last of 11)
- Kevin Charles Miller
- Patrick Connor Johnson
- Noopur S. Raje
- Content type: Article
- Open Access
- Published: 01 November 2022
- Blood Cancer Journal
- Article: 146
-
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia
Authors (first, second and last of 18)
- Valeria Ceolin
- Erica Brivio
- Christian Michel Zwaan
- Content type: Article
- Published: 30 October 2022
- Leukemia
- Pages: 53 - 60
-
The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer
Authors (first, second and last of 7)
- Haigang Ding
- Juan Zhang
- Qingping Li
- Content type: Review Article
- Published: 29 September 2022
- Medical Oncology
- Article: 232
-
Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis
Authors (first, second and last of 12)
- Hui Zhang
- Chaoke Bu
- Chunfu Li
- Content type: Article
- Published: 23 September 2022
- Leukemia
- Pages: 2596 - 2604
-
Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy
Authors (first, second and last of 24)
- Paolo Strati
- Andrew P. Jallouk
- Sattva S. Neelapu
- Content type: Article
- Published: 20 September 2022
- Leukemia
- Pages: 2669 - 2677
-
Delineation of a T-cell receptor CDR3-cancer mutanome aromaticity factor, assessable via blood samples, that facilitates the establishment of survival distinctions in bladder cancer
Authors (first, second and last of 7)
- Jacqueline Wahura Waweru
- Kennedy Wanjau Mwangi
- Francis W. Makokha
- Content type: Research
- Published: 13 September 2022
- Journal of Cancer Research and Clinical Oncology
- Pages: 4359 - 4366
-
High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion
Authors (first, second and last of 9)
- Ana Carolina Caballero
- Laura Escribà-Garcia
- Javier Briones
- Content type: Article
- Published: 29 August 2022
- Cancer Gene Therapy
- Pages: 51 - 61
-
Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction
Authors (first, second and last of 12)
- Penglei Jiang
- Zhaoru Zhang
- Pengxu Qian
- Content type: Article
- Published: 12 August 2022
- Leukemia
- Pages: 2656 - 2668
-
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
Authors (first, second and last of 19)
- Hassan B. Alkhateeb
- Razan Mohty
- Mithun Vinod Shah
- Content type: Correspondence
- Open Access
- Published: 26 July 2022
- Blood Cancer Journal
- Article: 113